TITLE:
Development of Non-ABO Red Blood Cell Alloantibodies in Patient Undergoing Allogeneic Haematopoietic Stem Cell Transplant
AUTHORS:
Ahmed Alsuhaibani, Khalid Batarfi, Ahmed Alharbi, Haya Alwasel, Abdullah Alenazi, Abdulmohsen Alotaibi, Jalal Hassan, Rayyan Alotaibi, Hajer Aziz, Nourah Alharethi, Sara Alobaidi, Maram Alonayzan, Sanad Alharthi, Majd Alanazi, Sarah Alotaibi, Ahmed Shareefi, Bandar Alqahtani
KEYWORDS:
Haematopoietic Stem Cell Transplant (HSCT), Non-ABO Red Blood Cell Antibodies, Alloantibodies
JOURNAL NAME:
Case Reports in Clinical Medicine,
Vol.13 No.5,
May
10,
2024
ABSTRACT: Alloantibodies that are non ABO Alloimmunization to protein antigens happens only after exposure, in contrast to ABO isohaemagglutinins, which are present naturally, even in the absence of prior exposure. It is recognized that while non-ABO RBC antibodies are less common than ABO antibodies, they generate essentially the same issues that lead to unfavorable clinical results. If non-ABO alloantibodies are identified early on, these issues related complications may be avoided This call for an in-depth understanding of the recipient and donor’s ABO-Rh grouping, antibody screening, and the phenotype of certain antigens. Equally important, the temporal association time between transplantation and hemolysis can help identify the underlying mechanism of hemolysis and direct appropriate management. Therefore, for that, it is crucial to identify the etiology of post-HSCT anemia for prevention and therapy, in addition to a thorough grasp of the mechanism of anemia in non-ABO-incompatible HSCT and the temporal link between HSCT and anemia. Finding the cause of post-HSCT anemia is essential for prevention and therapy, in addition to a thorough grasp of the mechanism of anemia in non-ABO-incompatible HSCT and the temporal link between HSCT and anemia. Therefore, for that, it is crucial to identify the etiology of post-HSCT anemia. In this case report review, we would like to highlight the vital role of transfusion medicine services and stem cell clinical teams in paying particular attention to the clinical significance of non-ABO alloantibodies involved to avoid causing overt hemolysis of incompatible donor RBCs or delayed erythropoiesis. Considering the fact that some of the Haematopoietic stem cell transplant centers do not give an attention to the other non-ABO RBC antigens.